SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-169360
Filing Date
2021-05-21
Accepted
2021-05-21 16:42:09
Documents
16
Period of Report
2021-05-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d88578d8k.htm   iXBRL 8-K 27218
2 EX-1.1 d88578dex11.htm EX-1.1 175934
3 EX-5.1 d88578dex51.htm EX-5.1 14925
7 GRAPHIC g885781snap0002.jpg GRAPHIC 5445
8 GRAPHIC g8857822snap0001.jpg GRAPHIC 3057
  Complete submission text file 0001193125-21-169360.txt   404973

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20210521.xsd EX-101.SCH 3085
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20210521_lab.xml EX-101.LAB 17374
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20210521_pre.xml EX-101.PRE 10963
9 EXTRACTED XBRL INSTANCE DOCUMENT d88578d8k_htm.xml XML 3234
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 21949703
SIC: 2834 Pharmaceutical Preparations